The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy
Background: Bladder cancer is a highly aggressive cancer, and muscle invasive urothelial carcinoma (MIUC) requires aggressive strategy. Concomitant chemo-radiotherapy (CRT) appears as a therapeutic option that allows bladder sparing. No biomarker is currently available to optimally select patients f...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/12/770 |
| _version_ | 1797381443693838336 |
|---|---|
| author | Hélène Houssiau Géraldine Pairet Hélène Dano Emmanuel Seront |
| author_facet | Hélène Houssiau Géraldine Pairet Hélène Dano Emmanuel Seront |
| author_sort | Hélène Houssiau |
| collection | DOAJ |
| description | Background: Bladder cancer is a highly aggressive cancer, and muscle invasive urothelial carcinoma (MIUC) requires aggressive strategy. Concomitant chemo-radiotherapy (CRT) appears as a therapeutic option that allows bladder sparing. No biomarker is currently available to optimally select patients for CRT. Methods: We retrospectively enrolled patients with MIUC who were treated in a curative setting with CRT. Based on c-MET expression in pre-treatment tumor tissue, patients were stratified into two groups: no expression of c-MET (group A) and expression of c-MET (group B). We evaluated the outcome of these patients based on c-MET expression. Results: After a median follow-up of 40 months, 13 patients were enrolled in this analysis, 8 in group A and 5 in group B. The disease recurrence was 25% in group A and 100% in group B. Compared to group A, patients from group B experienced more frequent and more rapid recurrence in terms of metastases; the 3-year metastatic recurrence rate was 13% and 100%, respectively. The c-MET expression was also associated with a higher rate of cancer-related deaths. Conclusions: In this retrospective analysis, c-MET expression was associated with worse disease-free survival and survival in patients treated radically with CRT. |
| first_indexed | 2024-03-08T20:51:37Z |
| format | Article |
| id | doaj.art-41cbfe835318403fb31bf49c6c699e21 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-08T20:51:37Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-41cbfe835318403fb31bf49c6c699e212023-12-22T14:02:28ZengMDPI AGCurrent Oncology1198-00521718-77292023-12-013012105501055510.3390/curroncol30120770The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-RadiotherapyHélène Houssiau0Géraldine Pairet1Hélène Dano2Emmanuel Seront3Department of Medical Oncology, Groupe Jolimont, 7100 Haine Saint Paul, BelgiumDepartment of Pathology, Groupe Jolimont, 7100 Haine Saint Paul, BelgiumDepartment of Pathology, Cliniques Universitaires Saint Luc, 1200 Brussels, BelgiumDepartment of Medical Oncology, Groupe Jolimont, 7100 Haine Saint Paul, BelgiumBackground: Bladder cancer is a highly aggressive cancer, and muscle invasive urothelial carcinoma (MIUC) requires aggressive strategy. Concomitant chemo-radiotherapy (CRT) appears as a therapeutic option that allows bladder sparing. No biomarker is currently available to optimally select patients for CRT. Methods: We retrospectively enrolled patients with MIUC who were treated in a curative setting with CRT. Based on c-MET expression in pre-treatment tumor tissue, patients were stratified into two groups: no expression of c-MET (group A) and expression of c-MET (group B). We evaluated the outcome of these patients based on c-MET expression. Results: After a median follow-up of 40 months, 13 patients were enrolled in this analysis, 8 in group A and 5 in group B. The disease recurrence was 25% in group A and 100% in group B. Compared to group A, patients from group B experienced more frequent and more rapid recurrence in terms of metastases; the 3-year metastatic recurrence rate was 13% and 100%, respectively. The c-MET expression was also associated with a higher rate of cancer-related deaths. Conclusions: In this retrospective analysis, c-MET expression was associated with worse disease-free survival and survival in patients treated radically with CRT.https://www.mdpi.com/1718-7729/30/12/770c-METbladder cancerradiotherapychemotherapymetastasis-free survivalbiomarker |
| spellingShingle | Hélène Houssiau Géraldine Pairet Hélène Dano Emmanuel Seront The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy Current Oncology c-MET bladder cancer radiotherapy chemotherapy metastasis-free survival biomarker |
| title | The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy |
| title_full | The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy |
| title_fullStr | The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy |
| title_full_unstemmed | The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy |
| title_short | The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy |
| title_sort | role of c met as a biomarker in patients with bladder cancer treated with radical chemo radiotherapy |
| topic | c-MET bladder cancer radiotherapy chemotherapy metastasis-free survival biomarker |
| url | https://www.mdpi.com/1718-7729/30/12/770 |
| work_keys_str_mv | AT helenehoussiau theroleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT geraldinepairet theroleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT helenedano theroleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT emmanuelseront theroleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT helenehoussiau roleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT geraldinepairet roleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT helenedano roleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy AT emmanuelseront roleofcmetasabiomarkerinpatientswithbladdercancertreatedwithradicalchemoradiotherapy |